摘要
目的:探讨人脐带间充质干细胞条件培养基联合白藜芦醇对人绒毛膜外滋养层细胞凋亡的影响。方法:通过CCK8细胞活力检测试剂盒测定白藜芦醇及其与人脐带间充质干细胞条件培养基共同处理人绒毛膜外滋养层细胞HTR8后对细胞增殖及活性的影响;细胞迁移试验检测白藜芦醇和人脐带间充质干细胞条件培养基对细胞迁移能力的影响;显微镜观察细胞形态,并用流式细胞仪检测细胞凋亡率的变化;Western blot检测白藜芦醇和人脐带间充质干细胞条件培养基对细胞凋亡相关蛋白Bax、Bcl-2以及迁移相关蛋白MMP-9表达的影响。结果:白藜芦醇能够抑制HTR8细胞增殖,抑制细胞迁移及MMP-9蛋白的表达,改变Bax和Bcl-2蛋白表达诱导细胞凋亡的作用。而人脐带间充质干细胞条件培养基能够逆转白藜芦醇对细胞的抑制作用。结论:人脐带间充质干细胞条件培养基能够通过调控Bax、Bcl-2、MMP-9的蛋白表达逆转白藜芦醇对人绒毛膜外滋养层细胞的抑制作用。人脐带间充质干细胞条件培养基可作为潜在的治疗人绒毛膜外滋养层细胞功能障碍的临床手段,孕妇需要小心使用白藜芦醇。
Objective: This study was aimed to assess the potential effects of resveratrol and human umbilical cord mesenchymal stem cells conditional medium on human chorionic trophoblast cells. Methods: The in vitro cultured HTR8 cells were treated with resveratrol and human umbilical cord mesenchymal stem cells conditional medium. Cell viability was analyzed by CCK8 assay. The cell migration was detected by the cell scratch test. The cell morphology changes were observed by light microscop and the cell apoptosis was detected by flow cytometer. The protein expressions of Bax, Bcl-2 and MMP-9 were measured by Western blot. Results: We found that resveratrol inhibited the cell viability and migration of HTR8 cells by decrease the expression of MMP-9. Meanwhile, resveratrol increased the apoptosis of HTR8 cells by inducing the imbalance between Bax and Bcl-2. However, these effects of resveratrol can be reversed by human umbilical cord mesenchymal stem cells conditional medium. Conclusion: Human umbilical cord mesenchymal stem cells conditional medium could relieve the inhibitory effect of resveratrol on human chorionic trophoblast cells by regulating the protein expressions of Bax, Bcl-2 and MMP-9. Pregnant women need to be careful when taking resveratrol and human umbilical cord mesenchymal stem cells conditional medium may be a potential therapeutic strategy for the dysfunction of chorionic trophoblast cells.
作者
张珦
李惠
章宜芬
范竞
李长印
蔡金洋
ZHANG Xiang;LI Hui;ZHANG Yi-fen;FAN Jing;LI Chang-yin;CAI Jin-yang(Department of Pathology,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing,Jiangsu,210000,China;Nanjing Medical University,Nanjing,Jiangsu,211166,China)
出处
《现代生物医学进展》
CAS
2020年第7期1253-1258,共6页
Progress in Modern Biomedicine
基金
南京医科大学科技发展基金面上项目(2017NJMU017)
江苏高校优势学科建设工程资助项目(苏政办发[2018]87号)
南京中医药大学中医学优势学科三期项目开放课题(ZYX03KF030)。